A Phase 2 interventional study of Placebo and leronlimab 700 mg in Nonalcoholic Steatohepatitis (NASH), sponsored by CytoDyn, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-01.
Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 174th largest by enrollment of the 460 interventional ones that give a count, is one of 39 that started in 2020, is one of 192 in phase 2, and was the 318th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 39 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 60 across 1,177 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
CytoDyn, Inc. has 1 study filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase II study of of Leronlimab (PRO 140)-Humanized monoclonal antibody to CCR5 in patients with Nonalcoholic Steatohepatitis (NASH).
This is an exploratory phase II, multi-center, two-part study (Part 1: randomized, placebo-controlled, two-arm with 60 patients; Part 2: non-randomized, single-arm, open-label with 30 patients) designed to evaluate the safety and efficacy of leronlimab after subcutaneous (SC) administration in patients with NASH for 13 weeks.
A Follow Up visit was conducted 28 (± 3) days after receiving the last study treatment (i.e., after last dose of Leronlimab (PRO 140) or placebo.
Inclusion Criteria: Subjects are required to meet ALL of the following criteria for enrollment into the study:
Evidence of nonalcoholic steatohepatitis (NASH) based on one of the following criteria:
Laboratory Screening results as indicated below:
Subjects with pre-diabetes or type 2 diabetes will be allowed to participate if the following criteria is met:
Exclusion Criteria: Subjects meeting ANY of the following criteria will be excluded from enrollment:
History of alcohol consumption greater than 21/units/week (for males) and 14/units/week (for females) within the last 2 years prior to screening.
Note: Use of online unit calculator for alcohol consumption is recommended (e.g., https://alcoholchange.org.uk/alcohol-facts/interactive-tools/unit-calculator)
Any condition requiring continuous systemic treatment with (such as corticosteroids) or immunomodulatory medications.
Note: Inhaled or topical steroids of up to 5 mg daily prednisone equivalent dose are permitted in the bsence of active autoimmune disease.
History of administration of a live, attenuated vaccine within four weeks prior to start of PRO 140 treatment or anticipation that such a will be required during the remainder of the study.
Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed. However intranasal influenza vaccines (e.g., Flu-Mist ®) are live attenuated vaccines, and are not allowed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leronlimab 700 mg SC weekly injection
Drug: leronlimab 700 mg
Leronlimab 350 mg SC weekly injection
Drug: leronlimab 350 mg
Placebo SC weekly injection
Drug: Placebo
Placebo will be administered subcutaneously every week for 13 weeks.
700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
Also known as: PRO 140
350 mg leronlimab will be administered subcutaneously every week for 13 weeks.
Also known as: PRO 140
MRI-PDFF Change From Baseline to Week 14
Change in hepatic fat fraction from baseline assessed by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) at week 14
Time frame: Change from baseline (day one, first day of treatment) to EOT (day 92, 13 weeks of treatment)
MRI-cT1 Change From Baseline to Week 14
MRI corrected T1 (cT1) is emerging as a promising quantitative surrogate metric for assessing a composite of liver inflammation and fibrosis.
Time frame: Measured at baseline (day 1) and at EOT (day 92)
Alkaline Phosphatase
Change from Baseline to Week 14 in Alkaline Phosphatase
Time frame: Measured at baseline (day 1) and at EOT (day 92)
Alanine Aminotraferase (ALT)
Change from Baseline to Week 14 in Alanine Aminotraferase (ALT)
Time frame: Measured at baseline (day 1) and at day 92
Aspartate Aminotransferase (AST)
Change from Baseline to Week 14 in Aspartate Aminotransferase (AST)
Time frame: Measured at baseline (day 1) and at EOT (day 92)
GGT S
Change from Baseline to Week 14 in Gamma Glutamyl transferase, GGT S
Time frame: Measured at baseline (day 1) and at EOT (day 92)
Neutrophils/Leukocytes
Change in Neutrophils/Leukocytes ratio from Baseline to Week 14
Time frame: Measured at baseline (day 1, start of treatment) and at EOT (day 92)
CCL2
Change from Baseline to Week 14 in Monocyte Chemotactic Protein 1 (CCL2)
Time frame: Measured at baseline (day 1) and at EOT (day 92)
CCL3
Change from Baseline (day 1, start of treatment) to Week 14 (EOT) in Macrophage Inflammatory Protein 1 Alpha
Time frame: Measured at baseline (day 1, start of treatment) and at EOT (day 92)
CCL5 (Rantes)
Change from Baseline to Week 14 in CCL-5 (Rantes)
Time frame: Measured at baseline (day 1) and at EOT (day 92)
Fibro Test Score
Change from baseline (day 1, start of treatment) to Week 14 (EOT) in Fibro Test Score measured on a scale of 0 to 1, where 0 to 0.27 is no fibrosis, 0.27 to 0.48 is minimal fibrosis, 0.48 to 0.58 is moderate fibrosis, 0.58 to 0.74 is advanced fibrosis and 0.74 to 1.00 is severe fibrosis (Cirrhosis). Minimum score is zero, maximum score (worst outcome) is 1.
Time frame: Measured at baseline (day 1, start of treatment) and at EOT (day 92)
CCL11( Eotaxin-1)
Change from Baseline to Week 14 in Eosinophils Chemotactic Protein
Time frame: Measured at baseline (day 1, start of treatment) and at EOT (day 92)
CCL18
Change from Baseline to week 14 in CCL18 (Pulmonary \& Activation-Reg Chemokine)
Time frame: Measured at baseline (day 1) and at EOT (day 92)
VCAM
Change from Baseline to Week 14 in Vascular Cell Adhesion Molecule 1
Time frame: Measured at baseline (day 1) and at EOT (day 92)
Interleukin-1 Beta
Change from Baseline to Week 14 in Interleukin-1 Beta
Time frame: Measured at baseline (day 1) and at EOT (day 92)
IL-1RA
Change from Baseline to Week 14 in Interleukin 1 Receptor Antagonist
Time frame: Measured at baseline (day 1) and at EOT (day 92)
IL-6
Change from Baseline to Week 14 in Interleukin 6
Time frame: Measured at baseline (day 1) and at EOT (day 92)
IL-8
Change from Baseline to Week 14 in Interleukin 8
Time frame: Measured at baseline (day 1) and at EOT (day 92)
TNF Receptor 2
Change from baseline (day 1, start of treatment) to Week 14 (EOT) in Tumor Necrosis Factor Receptor 2
Time frame: Measured at baseline (day 1, start of treatment) and at EOT (day 92)
TIMP-1
Change from Baseline (day 1, start of treatment) to Week 14 (EOT) in Tissue Inhibitor of Metalloproteinases 1 (ng/mL)
Time frame: Measured at baseline (day 1) and at EOT (day 92)
En Rage
Change from baseline (start of treatment, day 1) to Week 14 (EOT) in En Rage (Receptor Advanced Glycation End-Products)
Time frame: Measured at baseline (day 1) and at EOT (day 92)
| Milestone | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| Started | 30 | 27 | 30 |
| Completed | 24 | 21 | 28 |
| Not completed | 6 | 6 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Sponsor wish | 1 | 0 | 0 |
| Withdrew: Withdrawal of consent | 2 | 2 | 0 |
Change in hepatic fat fraction from baseline assessed by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) at week 14
| Percentage of hepatic fat fraction | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| MRI-PDFF Change From Baseline to Week 14 | -1.25 (-2.60 to 2.30) | -0.90 (-3.10 to 0.40) | 0.90 (-0.20 to 3.70) |
MRI corrected T1 (cT1) is emerging as a promising quantitative surrogate metric for assessing a composite of liver inflammation and fibrosis.
| Milliseconds (ms) | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| MRI-cT1 Change From Baseline to Week 14 | -7.0 (-35.0 to 22.0) | -2.00 (-54.00 to 24.00) | 22.0 (2.0 to 41.0) |
Change from Baseline to Week 14 in Alkaline Phosphatase
| IU/L | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| Alkaline Phosphatase | 0.37 ± 7.77 | -3.68 ± 7.99 | -0.83 ± 7.75 |
Change from Baseline to Week 14 in Alanine Aminotraferase (ALT)
| U/L | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| Alanine Aminotraferase (ALT) | 4.77 ± 32.06 | -0.76 ± 16.65 | 1.79 ± 18.83 |
Change from Baseline to Week 14 in Aspartate Aminotransferase (AST)
| U/L | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| Aspartate Aminotransferase (AST) | 1.40 ± 15.10 | -6.12 ± 33.33 | 2.17 ± 13.23 |
Change from Baseline to Week 14 in Gamma Glutamyl transferase, GGT S
| U/L | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| GGT S | 5.67 ± 14.12 | -3.00 ± 14.73 | 0.90 ± 11.61 |
Change in Neutrophils/Leukocytes ratio from Baseline to Week 14
| Ratio of neutrophils to leukocytes | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| Neutrophils/Leukocytes | 0.93 ± 5.94 | -4.32 ± 8.42 | 0.55 ± 6.07 |
Change from Baseline to Week 14 in Monocyte Chemotactic Protein 1 (CCL2)
| pg/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| CCL2 | 57.60 ± 175.98 | -77.0 ± 161.99 | -38.57 ± 140.75 |
Change from Baseline (day 1, start of treatment) to Week 14 (EOT) in Macrophage Inflammatory Protein 1 Alpha
| pg/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| CCL3 | 1.40 ± 6.22 | -7.20 ± 5.03 | -0.96 ± 2.62 |
Change from Baseline to Week 14 in CCL-5 (Rantes)
| ng/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| CCL5 (Rantes) | 8.14 ± 15.82 | -6.80 ± 44.40 | -0.39 ± 8.28 |
Change from baseline (day 1, start of treatment) to Week 14 (EOT) in Fibro Test Score measured on a scale of 0 to 1, where 0 to 0.27 is no fibrosis, 0.27 to 0.48 is minimal fibrosis, 0.48 to 0.58 is moderate fibrosis, 0.58 to 0.74 is advanced fibrosis and 0.74 to 1.00 is severe fibrosis (Cirrhosis). Minimum score is zero, maximum score (worst outcome) is 1.
| score on a scale | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| Fibro Test Score | 0.02 ± 0.06 | 0.01 ± 0.07 | -0.00 ± 0.06 |
Change from Baseline to Week 14 in Eosinophils Chemotactic Protein
| pg/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| CCL11( Eotaxin-1) | 29.30 ± 87.67 | -3.88 ± 95.10 | -41.32 ± 116.25 |
Change from Baseline to week 14 in CCL18 (Pulmonary \& Activation-Reg Chemokine)
| ng/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| CCL18 | 6.77 ± 36.16 | -27.28 ± 40.49 | -2.14 ± 34.43 |
Change from Baseline to Week 14 in Vascular Cell Adhesion Molecule 1
| ng/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| VCAM | 35.93 ± 178.64 | -82.80 ± 79.95 | 8.89 ± 109.96 |
Change from Baseline to Week 14 in Interleukin-1 Beta
| pg/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| Interleukin-1 Beta | 0.06 ± 0.31 | 0.09 ± 0.46 | 0.16 ± 0.61 |
Change from Baseline to Week 14 in Interleukin 1 Receptor Antagonist
| pg/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| IL-1RA | 6.37 ± 125.39 | -16.24 ± 74.40 | 15.93 ± 54.63 |
Change from Baseline to Week 14 in Interleukin 6
| pg/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| IL-6 | 0.17 ± 1.18 | -0.24 ± 0.68 | 0.31 ± 1.74 |
Change from Baseline to Week 14 in Interleukin 8
| pg/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| IL-8 | -3.25 ± 8.89 | -2.18 ± 7.81 | -0.54 ± 5.00 |
Change from baseline (day 1, start of treatment) to Week 14 (EOT) in Tumor Necrosis Factor Receptor 2
| pg/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| TNF Receptor 2 | 1.04 ± 3.25 | -1.66 ± 2.24 | 0.79 ± 1.72 |
Change from Baseline (day 1, start of treatment) to Week 14 (EOT) in Tissue Inhibitor of Metalloproteinases 1 (ng/mL)
| ng/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| TIMP-1 | 8.30 ± 32.39 | -11.76 ± 29.33 | 1.25 ± 25.62 |
Change from baseline (start of treatment, day 1) to Week 14 (EOT) in En Rage (Receptor Advanced Glycation End-Products)
| ng/mL | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| En Rage | 30.77 ± 229.87 | -60.40 ± 245.32 | 54.96 ± 141.75 |
Collected over 14 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Leronlimab 700 mg | 0/30 (0%) | 2/30 (6.7%) | 28/30 (93.3%) |
| Leronlimab 350 mg | 1/27 (3.7%) | 1/27 (3.7%) | 21/27 (77.8%) |
| Placebo | 0/30 (0%) | 2/30 (6.7%) | 21/30 (70%) |
| Event | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| ACCIDENTInjury, poisoning and procedural complications | 0/30 | 1/27 | 0/30 |
| TOOTH ABSCESSGastrointestinal disorders | 0/30 | 0/27 | 1/30 |
| EYE INFECTION BACTERIALInfections and infestations | 1/30 | 0/27 | 0/30 |
| INVASIVE DUCTAL BREAST CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/30 | 0/27 | 0/30 |
| RENAL IMPAIRMENTRenal and urinary disorders | 0/30 | 0/27 | 1/30 |
| Event | Leronlimab 700 mg | Leronlimab 350 mg | Placebo |
|---|---|---|---|
| C-reactive protein increasedInvestigations | 7/30 | 8/27 | 3/30 |
| Abdominal PainGastrointestinal disorders | 5/30 | 2/27 | 4/30 |
| DiarrhoeaGastrointestinal disorders | 5/30 | 2/27 | 2/30 |
| Urinary tract infectionRenal and urinary disorders | 5/30 | 3/27 | 3/30 |
| HyperglycaemiaEndocrine disorders | 4/30 | 0/27 | 1/30 |
| HypertensionVascular disorders | 2/30 | 3/27 | 1/30 |
| Injection site painInjury, poisoning and procedural complications | 3/30 | 1/27 | 2/30 |
| Blood Creatine Phosphokinase IncreasedInvestigations | 1/30 | 1/27 | 3/30 |
| HypercalcaemiaMetabolism and nutrition disorders | 3/30 | 0/27 | 1/30 |
| Alanine aminotransferase increasedInvestigations | 0/30 | 2/27 | 2/30 |
Patients with Nonalcoholic Steatohepatitis (NASH)
| Age, Continuous(years) | Leronlimab 700 mg | Leronlimab 350 mg | Placebo | Total |
|---|---|---|---|---|
| Age | 53.2 ± 13.68 | 52.4 ± 8.38 | 55.6 ± 10.47 | 53.80 ± 11.1 |
| Sex: Female, Male(Participants) | Leronlimab 700 mg | Leronlimab 350 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 19 | 13 | 9 | 41 |
| Male | 11 | 14 | 21 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Leronlimab 700 mg | Leronlimab 350 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 16 | 16 | 12 | 44 |
| Not Hispanic or Latino | 14 | 11 | 18 | 43 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Leronlimab 700 mg | Leronlimab 350 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 5 | 2 | 7 |
| White | 30 | 22 | 28 | 80 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| BMI(kg/m^2) | Leronlimab 700 mg | Leronlimab 350 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 41.2 ± 9.56 | 38.0 ± 5.52 | 38.4 ± 5.89 | 39.2 ± 7.33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Dec 2021, 12 months.
Results were first posted in Mar 2023, 1 year 2 months after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 12 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leronlimab
Non-alcoholic Fatty Liver Disease →